Brokerages expect that Nektar Therapeutics (NASDAQ:NKTR) will announce earnings of ($0.40) per share for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Nektar Therapeutics’ earnings. The highest EPS estimate is ($0.28) and the lowest is ($0.54). Nektar Therapeutics reported earnings per share of ($0.14) in the same quarter last year, which suggests a negative year-over-year growth rate of 185.7%. The firm is expected to announce its next quarterly earnings results on Tuesday, May 2nd.
According to Zacks, analysts expect that Nektar Therapeutics will report full-year earnings of ($1.19) per share for the current year, with EPS estimates ranging from ($1.56) to ($0.65). For the next year, analysts anticipate that the firm will report earnings of ($0.97) per share, with EPS estimates ranging from ($1.92) to ($0.28). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Nektar Therapeutics.
Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Wednesday, March 1st. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.02. Nektar Therapeutics had a negative return on equity of 8,769.15% and a negative net margin of 98.87%. The company had revenue of $37.45 million for the quarter, compared to analyst estimates of $40.83 million. During the same period last year, the company posted ($0.40) EPS. The business’s revenue for the quarter was down 4.9% on a year-over-year basis.
Several equities analysts have commented on the company. Roth Capital set a $23.00 price target on Nektar Therapeutics and gave the company a “buy” rating in a report on Saturday, March 4th. Piper Jaffray Companies reiterated an “overweight” rating and set a $29.00 price target on shares of Nektar Therapeutics in a report on Tuesday, April 11th. BTIG Research assumed coverage on Nektar Therapeutics in a report on Friday, January 6th. They set a “buy” rating and a $22.00 price target on the stock. Aegis reiterated a “buy” rating and set a $21.00 price target on shares of Nektar Therapeutics in a report on Wednesday, December 28th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $17.00 price target (up previously from $15.00) on shares of Nektar Therapeutics in a report on Friday, March 3rd. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $25.50.
ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Anticipate Nektar Therapeutics (NKTR) Will Post Earnings of -$0.40 Per Share” was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.themarketsdaily.com/2017/04/21/zacks-analysts-anticipate-nektar-therapeutics-nktr-will-post-earnings-of-0-40-per-share.html.
In other news, Director Christopher A. Kuebler sold 15,000 shares of the firm’s stock in a transaction on Wednesday, April 5th. The shares were sold at an average price of $21.88, for a total value of $328,200.00. Following the sale, the director now owns 50,500 shares in the company, valued at $1,104,940. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Gil M. Labrucherie sold 2,359 shares of the firm’s stock in a transaction on Thursday, February 16th. The stock was sold at an average price of $13.14, for a total transaction of $30,997.26. The disclosure for this sale can be found here. In the last 90 days, insiders sold 697,689 shares of company stock worth $11,991,678. 6.10% of the stock is currently owned by corporate insiders.
Several large investors have recently made changes to their positions in the company. BlackRock Fund Advisors increased its stake in shares of Nektar Therapeutics by 7.3% in the third quarter. BlackRock Fund Advisors now owns 10,970,974 shares of the biopharmaceutical company’s stock valued at $188,481,000 after buying an additional 749,496 shares during the last quarter. US Bancorp DE increased its stake in shares of Nektar Therapeutics by 0.7% in the third quarter. US Bancorp DE now owns 94,005 shares of the biopharmaceutical company’s stock valued at $1,615,000 after buying an additional 665 shares during the last quarter. UBS Asset Management Americas Inc. increased its stake in shares of Nektar Therapeutics by 4.3% in the third quarter. UBS Asset Management Americas Inc. now owns 121,114 shares of the biopharmaceutical company’s stock valued at $2,080,000 after buying an additional 4,990 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Nektar Therapeutics by 12.1% in the third quarter. PNC Financial Services Group Inc. now owns 24,084 shares of the biopharmaceutical company’s stock valued at $414,000 after buying an additional 2,601 shares during the last quarter. Finally, KBC Group NV increased its stake in shares of Nektar Therapeutics by 116.3% in the third quarter. KBC Group NV now owns 47,413 shares of the biopharmaceutical company’s stock valued at $815,000 after buying an additional 25,496 shares during the last quarter. Institutional investors and hedge funds own 86.80% of the company’s stock.
Shares of Nektar Therapeutics (NASDAQ:NKTR) traded down 3.97% during trading on Tuesday, reaching $18.37. 2,793,643 shares of the company traded hands. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $24.88. The firm’s market capitalization is $2.83 billion. The firm has a 50-day moving average price of $19.09 and a 200-day moving average price of $14.78.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.